IQVIA Holdings Inc. (NYSE:IQV) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• IQVIA Holdings Inc. has received an average recommendation of "Moderate Buy" from 23 brokerages, with six holding and seventeen buying the stock, setting an average 12-month target price of $229.86.
• Recent analyst updates include JPMorgan lowering its price target from $232 to $177, while Robert W. Baird raised theirs from $159 to $196, indicating mixed sentiments among analysts.
• In its latest earnings report, IQVIA posted a quarterly earnings per share of $2.81, exceeding estimates and reflecting a 5.3% revenue increase compared to the same quarter last year.

IQVIA Holdings Inc. (NYSE:IQV - Get Free Report) has received an average recommendation of "Moderate Buy" from the twenty-three brokerages that are presently covering the firm, MarketBeat reports. Six investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $229.8571.

A number of analysts recently weighed in on the stock. Cowen reaffirmed a "buy" rating on shares of IQVIA in a report on Wednesday, July 23rd. JPMorgan Chase & Co. dropped their price objective on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a report on Monday, May 19th. Robert W. Baird increased their price objective on shares of IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a report on Wednesday, July 23rd. Redburn Partners set a $214.00 target price on shares of IQVIA in a research report on Wednesday. Finally, William Blair reiterated an "outperform" rating on shares of IQVIA in a research report on Wednesday, July 23rd.

Insider Transactions at IQVIA

In related news, insider Keriann Cherofsky sold 549 shares of the stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares in the company, valued at $557,352.30. This represents a 15.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the transaction, the insider owned 27,178 shares of the company's stock, valued at $5,165,178.90. This represents a 17.59% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company's stock.

Hedge Funds Weigh In On IQVIA

A number of institutional investors and hedge funds have recently bought and sold shares of IQV. American National Bank & Trust bought a new position in shares of IQVIA during the 1st quarter valued at about $26,000. Clal Insurance Enterprises Holdings Ltd boosted its position in shares of IQVIA by 436.7% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock valued at $28,000 after purchasing an additional 131 shares in the last quarter. Golden State Wealth Management LLC boosted its position in shares of IQVIA by 295.5% during the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after purchasing an additional 130 shares in the last quarter. AllSquare Wealth Management LLC bought a new position in shares of IQVIA during the 1st quarter valued at about $33,000. Finally, ST Germain D J Co. Inc. boosted its position in shares of IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after purchasing an additional 76 shares in the last quarter. Institutional investors own 89.62% of the company's stock.

IQVIA Stock Up 2.0%

IQV stock opened at $187.75 on Monday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. IQVIA has a fifty-two week low of $134.65 and a fifty-two week high of $249.43. The firm's 50-day simple moving average is $179.88 and its 200 day simple moving average is $167.23. The stock has a market cap of $31.92 billion, a PE ratio of 27.17, a price-to-earnings-growth ratio of 2.06 and a beta of 1.32.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business had revenue of $4.02 billion for the quarter, compared to analysts' expectations of $3.96 billion. During the same quarter last year, the company earned $2.64 EPS. The company's revenue for the quarter was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, sell-side analysts predict that IQVIA will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.